Guidelines on the management of Waldenström macroglobulinaemia.

Johnson, S A; Birchall, J; Luckie, C; Oscier, D G; Owen, R G

Johnson, S A; Birchall, J; Luckie, C; Oscier, D G; Owen, R G.

Affiliation

Johnson SA; Taunton and Somerset NHS Trust, Taunton, UK.

Br J Haematol ; 132(6): 683-97, 2006 Mar.

Article in En | MEDLINE | ID: mdl-16487169

Subject(s)

Waldenstrom Macroglobulinemia/therapy; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Murine-Derived; Cladribine/therapeutic use; Drug Therapy, Combination; Enzyme Inhibitors/therapeutic use; Humans; Immunologic Factors/therapeutic use; Immunosuppressive Agents/therapeutic use; Plasma Exchange; Prognosis; Rituximab; Stem Cell Transplantation/methods; Thalidomide/therapeutic use; Vidarabine/analogs & derivatives; Vidarabine/therapeutic use; Waldenstrom Macroglobulinemia/drug therapy; Waldenstrom Macroglobulinemia/immunology

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Waldenstrom Macroglobulinemia Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: Br J Haematol Year: 2006 Document type: Article

Search on Google

XML

PubMed Links